Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MaaT Pharma S.A. (MAAT.PA)
Lyon, FR
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +7.75% | -14.67% | -51.28% | -60.42% | -31.16% | -40.75% | -43.90% | -64.38% | -79.57% | -79.57% | -79.57% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 1 | +1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+40.7% ★ Q4'25: +146.7% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+11.4% Q4'25: +2.1% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-433.4% Q4'25: -45.2% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%-754.9% Q4'25: -806.2% (vs Q4'23)
-
ROIC Biotechnology: -16.1%— Q4'25: +1,098.7% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+22.0% Q4'25: +44.8% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.54× Q4'25: -0.27× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
Dec 2029 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
972.0K
est: 1.00M (-2.8%)
|
1.43M
est: 2.15M (-33.5%)
|
2.23M
est: 2.57M (-13.3%)
|
3.22M
est: 2.97M (+8.1%)
|
4.52M
est: 10.91M (-58.5%)
|
8.96M
3.68M – 17.02M
-17.9% YoY
|
19.00M
1.25M – 45.00M
+111.9% YoY
|
11.94M
1.82M – 26.87M
-37.1% YoY
|
11.70M
1.79M – 26.33M
-2.0% YoY
|
| EBITDA |
-8.57M
est: -600.0K (-1,328.3%)
|
-13.10M
est: -1.29M (-915.4%)
|
-22.07M
est: -2.57M (-758.3%)
|
-26.34M
est: -2.97M (-785.7%)
|
-32.42M
est: -10.91M (-197.0%)
|
-8.96M
-17.02M – -3.68M
+17.9% YoY
|
-19.00M
-45.00M – -1.25M
-111.9% YoY
|
-11.94M
-26.87M – -1.82M
+37.1% YoY
|
-11.70M
-26.33M – -1.79M
+2.0% YoY
|
| EBIT |
-8.89M
est: -600.0K (-1,382.2%)
|
-13.56M
est: -1.29M (-950.9%)
|
-22.94M
est: -2.57M (-792.1%)
|
-28.04M
est: -2.97M (-842.6%)
|
-34.15M
est: -10.91M (-212.9%)
|
-8.96M
-17.02M – -3.68M
+17.9% YoY
|
-19.00M
-45.00M – -1.25M
-111.9% YoY
|
-11.94M
-26.87M – -1.82M
+37.1% YoY
|
-11.70M
-26.33M – -1.79M
+2.0% YoY
|
| Net Income |
-9.02M
est: -15.86M (+43.1%)
|
-13.71M
est: -14.73M (+6.9%)
|
-19.72M
est: -24.14M (+18.3%)
|
-28.90M
est: -31.13M (+7.2%)
|
-31.06M
est: -31.06M (+0.0%)
|
-31.69M
-40.91M – -20.53M
-2.0% YoY
|
-15.31M
-58.60M – 19.76M
+51.7% YoY
|
-33.90M
-62.62M – 2.42M
-121.4% YoY
|
-20.43M
-53.64M – 2.07M
+39.7% YoY
|
| SGA |
1.38M
est: 1.41M (-2.1%)
|
1.81M
est: 3.04M (-40.4%)
|
5.10M
est: 4.03M (+26.6%)
|
3.51M
est: 4.66M (-24.7%)
|
7.96M
est: 17.09M (-53.4%)
|
14.03M
5.76M – 26.66M
-17.9% YoY
|
29.74M
1.96M – 70.46M
+111.9% YoY
|
18.69M
2.86M – 42.07M
-37.1% YoY
|
18.32M
2.80M – 41.22M
-2.0% YoY
|
| EPS |
-3.72
est: -1.21 (-206.5%)
|
-1.39
est: -1.50 (+7.6%)
|
-1.73
est: -2.03 (+14.7%)
|
-2.20
est: -1.92 (-14.4%)
|
-1.95
est: -3.45 (+43.5%)
|
-1.81
-2.57 – -1.29
+47.5% YoY
|
-1.75
-3.68 – 1.24
+3.6% YoY
|
-1.50
-3.93 – 0.15
+14.3% YoY
|
-1.28
-3.37 – 0.13
+14.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Herve Affagard | Chief Executive Officer, Co-Founder & Director | 489.4K | male |
| Emilie Plantamura | Deputy Chief Medical Officer | — | — |
| Eric Soyer | Chief Financial Officer | — | male |
| Frederic Fasano | Chief Strategy & Corporate Development Officer | — | — |
| Guilhaume Debroas | Head of Investor Relations | — | — |
| Joel Dore | Co-Founder & Member of Scientific Advisory Board | — | — |
| Pierre Rimbaud | Co-Founder | — | male |
| Sheri Simmons | Acting Chief Scientific Officer | — | female |
| Carole Schwintner | Technology Director & Chief Technology Officer | — | female |
| Sian Crouzet | Chief of Staff | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MAAT.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
